blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1755589

EP1755589 - METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  24.04.2009
Database last updated on 22.05.2024
Most recent event   Tooltip24.04.2009Application deemed to be withdrawnpublished on 27.05.2009  [2009/22]
Applicant(s)For all designated states
CELGENE CORPORATION
86 Morris Avenue
Summit, NJ 07901 / US
[2007/09]
Inventor(s)01 / ZELDIS, Jerome, B.
157 Christopher Drive
Princeton, NJ 08540 / US
 [2007/09]
Representative(s)Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
[N/P]
Former [2008/43]Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11
80538 München / DE
Former [2007/09]Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte Prinzregentenstrasse 11
D-80538 München / DE
Application number, filing date05749368.621.04.2005
[2007/09]
WO2005US13597
Priority number, dateUS20040565174P23.04.2004         Original published format: US 565174 P
[2007/09]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2005102317
Date:03.11.2005
Language:EN
[2005/44]
Type: A1 Application with search report 
No.:EP1755589
Date:28.02.2007
Language:EN
The application published by WIPO in one of the EPO official languages on 03.11.2005 takes the place of the publication of the European patent application.
[2007/09]
Search report(s)International search report - published on:US03.11.2005
(Supplementary) European search report - dispatched on:EP10.10.2007
ClassificationIPC:A61K45/00, A61K45/06
[2007/45]
CPC:
A61K45/06 (EP,US); A61K31/397 (EP,KR,US); A61K31/366 (EP,US);
A61K31/40 (EP,KR,US); A61K31/4035 (EP,KR,US); A61K31/519 (EP,KR,US);
A61K31/704 (EP,US); A61K31/7048 (EP,US); A61P11/00 (EP);
A61P9/12 (EP) (-)
C-Set:
A61K31/7048, A61K2300/00 (EP,US)
Former IPC [2007/09]A61K31/40, A61K31/397
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2007/09]
Extension statesAL22.11.2006
BA22.11.2006
HR22.11.2006
LV22.11.2006
MK22.11.2006
YU22.11.2006
TitleGerman:VERFAHREN ZUR VERWENDUNG VON PDE4-MODULATOREN UND DIESE ENTHALTENDE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG UND KONTROLLE VON PULMONALER HYPERTONIE[2007/09]
English:METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR THE TREATMENT AND MANAGEMENT OF PULMONARY HYPERTENSION[2007/09]
French:PROCEDE D'UTILISATION DE MODULATEURS DE PDE4 ET COMPOSITIONS LES RENFERMANT POUR LE TRAITEMENT ET LA GESTION DE L'HYPERTENSION PULMONAIRE[2007/09]
Entry into regional phase22.11.2006National basic fee paid 
22.11.2006Search fee paid 
22.11.2006Designation fee(s) paid 
22.11.2006Examination fee paid 
Examination procedure18.11.2005Request for preliminary examination filed
International Preliminary Examining Authority: US
22.11.2006Examination requested  [2007/09]
18.01.2007Amendment by applicant (claims and/or description)
17.07.2008Despatch of a communication from the examining division (Time limit: M04)
28.11.2008Application deemed to be withdrawn, date of legal effect  [2009/22]
07.01.2009Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time  [2009/22]
Fees paidRenewal fee
12.04.2007Renewal fee patent year 03
31.03.2008Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO0066584  (WARNER LAMBERT CO [US], et al) [X] 1-10 * page 1, line 5 - line 9 ** page 49, line 5 - line 15 *;
 [X]WO0164647  (SANOFI SYNTHELABO [FR], et al) [X] 1-10 * page 1, line 3 - line 14 * * page 5, line 8 - line 14 *;
 [X]  - WAGNER R S ET AL, "Phosphodiesterase inhibition improves agonist-induced relaxation of hypertensive pulmonary arteries", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, (1997), vol. 282, no. 3, ISSN 0022-3565, pages 1650 - 1657, XP002285577 [X] 1-10 * abstract * * page 1654, column R, paragraph 3 * * page 1656, column R *
 [X]  - GHOFRANI H A ET AL, "Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20021101), Database accession no. EMB-2002422270, XP002452922 [X] 1-10 * abstract *
 [X]  - SCHERMULY R T ET AL, "Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension", MEDLINE, (199911), XP002235430 [X] 1-10 * abstract *
 [X]  - SCHERMULY R T ET AL, "Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTIC, US, (200002), vol. 292, no. 2, ISSN 0022-3565, pages 512 - 520, XP002307273 [X] 1-10 * abstract *
    [ ] - CRITICAL CARE MEDICINE 01 NOV 2002 UNITED STATES, (20021101), vol. 30, no. 11, ISSN 0090-3493, pages 2489 - 2492
International search[Y]US5877200  (MULLER GEORGE W [US]);
 [Y]US6214857  (MULLER GEORGE W [US], et al);
 [Y]WO0134606  (CELGENE CORP [US], et al);
 [X]US6239130  (PASCAL YVES [FR], et al);
 [Y]US6667316  (MAN HON-WAH [US], et al);
 [Y]US2004005306  (LOSCALZO JOSEPH [US], et al);
 [Y]US2004077624  (FOX DAVID NATHAN ABRAHAM [GB], et al);
 [Y]  - RUBIN L. ET AL., Primary Pulmonary Hypertension: Lung Biology in Health and Disease., (1997), vol. 99, pages 278 - 282, XP008052480
 [Y]  - KLINGS E. AND FARBER H. ET AL., "Current management of primary pulmonary hypertension.", DRUGS, (2001), vol. 61, no. 13, pages 1945 - 1956, XP001119696

DOI:   http://dx.doi.org/10.2165/00003495-200161130-00005
 [Y]  - PASS S. AND DUSING M. ET AL., "Current and energing therapy for primary pulmonary hypertension.", ANNALS PF PHARMACOTHERAPY, (200209), vol. 36, pages 1414 - 1423, XP008052646

DOI:   http://dx.doi.org/10.1345/aph.1C015
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.